References
- Arend R, Doneza JA, Wright JD (2011). Uterine carcinosarcoma. Curr Opin Oncol, 23, 531-6.
- Brown E, Stewart M, Rye T, et al (2004). Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer, 100, 2148-53. https://doi.org/10.1002/cncr.20256
- Clayton SD, Kenneth MO, Gaffney DK, et al (2008). The impact of adjuvant radiation therapy on survival in women with uterine carcinosarcoma. Radiother Oncol, 88, 227-32. https://doi.org/10.1016/j.radonc.2007.11.029
- Denschlag D, Masoud I, Stanimir G, et al (2007). Prognostic factors and outcome in women with uterine sarcoma. Eur J Surg Oncol, 33, 91-5. https://doi.org/10.1016/j.ejso.2006.11.012
- Einstein MH, Klobocista M, Hou JY, et al (2012). Phase II trial of adjuvant pelvic radiation “sandwiched” between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma. Gynecol Oncol, 124, 26-30. https://doi.org/10.1016/j.ygyno.2011.10.008
- Ferrer F, Sabater S, Farrus B, et al (1999). Impact of radiotherapy on local control and survival in uterine sarcomas: a retrospective study from the Group Oncologic Catala-Occita. Int J Radiat Oncol Biol Phys, 44, 47-52. https://doi.org/10.1016/S0360-3016(98)00515-X
- Gadducci A, Cosio S, Romanini A, Genazzani AR (2008). The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol, 65, 129-42. https://doi.org/10.1016/j.critrevonc.2007.06.011
- Gonzalez BJ, Terstriep SA, Cliby WA, et al (2010). The impact of multi-modal therapy on survival for uterine carcinosarcomas. Gynecol Oncol, 116, 419-23. https://doi.org/10.1016/j.ygyno.2009.10.053
- Homesley HD, Filiaci V, Markman M, et al (2007). Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a gynecologic oncology group study. J Clin Oncol, 25, 526-31. https://doi.org/10.1200/JCO.2006.06.4907
- Hoskins PJ, Le N, Ellard S, et al (2008). British columbia cancer agency. Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. the british columbia cancer agency experience. Gynecol Oncol, 108, 58-62. https://doi.org/10.1016/j.ygyno.2007.08.084
- Makker V, Abu-Rustum NR, Alektiar KM, et al (2008). A retrospective assessment of outcomes of chemotherapybased versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma. Gynecol Oncol, 111, 249-54. https://doi.org/10.1016/j.ygyno.2008.06.035
- McCluggage WG (2002). Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer, 12, 687-90. https://doi.org/10.1046/j.1525-1438.2002.01151.x
- Menczer J, Levy T, Piura B, et al (2005). A comparison between different postoperative treatment modalities of uterine carcinosarcoma. Gynecol Oncol, 97, 166-70. https://doi.org/10.1016/j.ygyno.2004.12.006
- Miller DS, King LP (2008). Gynecologic oncology group trials in uterine corpus malignancies: recent progress. J Gynecol Oncol, 19, 218-22. https://doi.org/10.3802/jgo.2008.19.4.218
- Nemani D, Mitra N, Guo M, et al (2008). Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol, 111, 82-8. https://doi.org/10.1016/j.ygyno.2008.05.016
- Powell MA, Filiaci VL, Rose PG, et al (2010). Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. J Clin Oncol, 28, 2727-31. https://doi.org/10.1200/JCO.2009.26.8326
- Reed NS, Mangioni C, Malmstrom H, et al (2008). European organisation for research and treatment of cancer gynaecological cancer group. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European organisation for research and treatment of cancer gynaecological cancer group study (protocol 55874). Eur J Cancer, 44, 808-18. https://doi.org/10.1016/j.ejca.2008.01.019
- Tanner EJ, Leitao MM Jr, Garg K, et al (2011). The role of cytoreductive surgery for newly diagnosed advanced-stage uterine carcinosarcoma. Gynecol Oncol, 123, 548-52. https://doi.org/10.1016/j.ygyno.2011.08.020
- Toyoshima M, Akahira J, Matsunaga G, et al (2004). Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus. Gynecol Oncol, 94, 774-8. https://doi.org/10.1016/j.ygyno.2004.05.048
- Sutton G, Brunetto VL, Kilgore L, et al (2000). A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol, 79, 147-53. https://doi.org/10.1006/gyno.2000.6001
- Sutton G, Kauderer J, Carson LF, et al (2005). Gynecologic oncology group. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a gynecologic oncology group study. Gynecol Oncol, 96, 630-4. https://doi.org/10.1016/j.ygyno.2004.11.022
- Wolfson AH, Brady MF, Rocereto T, et al (2007). A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol, 107, 177-85. https://doi.org/10.1016/j.ygyno.2007.07.070
- Wong L, See HT, Khoo-Tan HS, et al (2006). Combined adjuvant cisplatin and ifosfamide chemotherapy and radiotherapy for malignant mixed mullerian tumors of the uterus. Int J Gynecol Cancer, 16, 1364-9 https://doi.org/10.1111/j.1525-1438.2006.00560.x
Cited by
- Clinical Study on Carboplatin for Treating Pediatric Patients with Wilms Tumors vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7277
- Clinical Outcomes of Uterine Carcinosarcoma vol.25, pp.2, 2015, https://doi.org/10.1097/IGC.0000000000000347